Study ID: Alliance A091305
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Miroslaw Mazurczak, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.